文献速递脑血管病癫痫

直接口服抗凝药与抗癫痫发作药物联用于心房颤动合并癫痫患者及血栓栓塞事件风险

Direct-Acting Oral Anticoagulants and Antiseizure Medications for Atrial Fibrillation and Epilepsy and Risk of Thromboembolic Events.
PubMed 文献 · JAMA Neurol · 2024-01-01

该队列研究纳入美国健康数据库2010年10月至2021年9月的心房颤动合并癫痫成人患者,比较直接口服抗凝药(DOAC)联用酶诱导抗癫痫发作药物(EI ASM)与联用非酶诱导ASM者的血栓栓塞和大出血事件。结果显示联用EI ASM与血栓栓塞风险无显著差异(AHR 1.10,95%CI 0.82-1.46),但与重大出血风险降低相关(AHR 0.63,95%CI 0.44-0.89)。

要点

  • 联用EI ASM与血栓栓塞风险无显著差异(AHR 1.10,95%CI 0.82-1.46)。
  • 联用EI ASM与重大出血风险降低相关(AHR 0.63,95%CI 0.44-0.89)。
  • 作者认为EI ASM未改变DOAC疗效,出血风险降低需进一步研究。

核心结论

  • 在这项队列研究中,酶诱导抗癫痫发作药物与DOAC疗效改变无关。
  • 作者认为,酶诱导抗癫痫发作药物相关的出血风险降低需进一步研究,这可能提示药代动力学相互作用与降低DOAC水平相关而未抵消治疗效应。

研究设计与样本

  • 活性对照、新使用者队列研究,使用美国Clinformatics Data Mart数据库2010年10月至2021年9月的数据,纳入具有全国代表性的心房颤动合并癫痫成人患者。
  • 血栓栓塞结局评估纳入14078个DOAC与ASM新使用 episodes(中位年龄74岁,IQR 67-81;52.4%女性),重大出血结局评估纳入14158个 episodes(中位年龄74岁,IQR 67-81;52.4%女性)。
  • 暴露为DOAC与EI ASM连续联用(暴露组)或DOAC与非EI ASM连续联用(参照组)。
  • 采用数据自适应高维倾向评分匹配控制观察到的混杂因素及未观察混杂因素的代理变量,使用Cox比例风险回归模型(稳健方差估计量)估计校正风险比(AHR)。

主要发现

  • 血栓栓塞事件发生率为每1000人年88.5例,出血事件发生率为每1000人年68.3例。
  • 与非EI ASM相比,EI ASM联用DOAC与血栓栓塞事件风险无差异(AHR 1.10;95%CI 0.82-1.46)。
  • 与非EI ASM相比,EI ASM联用DOAC与重大出血事件风险降低相关(AHR 0.63;95%CI 0.44-0.89)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Direct-acting oral anticoagulants (DOACs) are commonly prescribed with antiseizure medications (ASMs) due to concurrency of and the association between atrial fibrillation (AF) and epilepsy. However, enzyme-inducing (EI) ASMs may reduce absorption and accelerate metabolism of DOACs, potentially lowering DOAC levels and elevating thromboembolism risk. OBJECTIVE: To assess the rates of thromboembolic and major bleeding events in adults with AF and epilepsy dispensed DOACs and EI ASMs vs DOACs with non-EI ASMs. DESIGN, SETTING, AND PARTICIPANTS: This active-comparator, new-user cohort study included US health care data from the Clinformatics Data Mart database from October 2010 to September 2021 for a nationally representative population of adults with AF and epilepsy. EXPOSURE: Evaluations included episodes of contiguous coadministration of DOACs for AF with EI ASMs (exposed) or non-EI ASMs (referent) for epilepsy. MAIN OUTCOMES AND MEASURES: Thromboembolic events (primary outcome) and major bleeding events (secondary outcome) were identified based on a series of validated, diagnosis-based coding algorithms. Data-adaptive, high-dimensional propensity score matching was used to control for observed confounders and proxies for unobserved confounders. Adjusted hazard ratios (AHRs) were estimated using Cox proportional hazards regression models with robust variance estimators to account for clustering within matched pairs. RESULTS: This study included 14 078 episodes (median age, 74 [IQR, 67-81]; 52.4% female) and 14 158 episodes (median age, 74 [IQR, 67-81]; 52.4% female) of incident DOAC and ASM use that met eligibility criteria for assessment of thromboembolic and major bleeding outcomes, respectively. Incidence was 88.5 per 1000 person-years for thromboembolic events and 68.3 per 1000 person-years for bleeding events. Compared with use of non-EI ASMs, use of EI ASMs with DOACs was not associated with a difference in risk of thromboembolic events (AHR, 1.10; 95% CI, 0.82-1.46) but was associated with a reduction in risk of major bleeding events (AHR, 0.63; 95% CI, 0.44-0.89). CONCLUSIONS AND RELEVANCE: In this cohort study, EI ASMs were not associated with alteration in DOAC efficacy. Further research is needed on the reduction in bleeding risk associated with EI ASMs, as this may suggest that pharmacokinetic interactions are associated with lowering DOAC levels without negating therapeutic effects.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Acton EK, Hennessy S, Gelfand MA, et al. Direct-Acting Oral Anticoagulants and Antiseizure Medications for Atrial Fibrillation and Epilepsy and Risk of Thromboembolic Events. JAMA Neurol. 2024. PMID: 38976246. doi:10.1001/jamaneurol.2024.2057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。